FREE Account Opening + No Clearing Fees
Loading...

Aasaan Loans IPO vs Emcure Pharma IPO

Comparision between Aasaan Loans IPO and Emcure Pharma IPO.

IPO Details

Aasaan Loans IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Emcure Pharma IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

  Aasaan Loans IPO Emcure Pharma IPO
Logo Aasaan Loans IPO Logo Emcure Pharma IPO Logo
Issue Category Mainline Mainline
Issue Type IPO IPO
Process Type Book Built Issue Book Built Issue
Listing At BSE, NSE BSE, NSE
Lead Managers Gretex Corporate Services Limited Kotak Mahindra Capital Company Limited

Axis Capital Limited

Jefferies India Private Limited

J.P. Morgan India Private Limited
Registrar Bigshare Services Pvt Ltd Link Intime India Private Ltd
Market Maker
DRHP DRHP DRHP
RHP RHP
Anchor Investor Anchor Investor
IPO Allotment URL

Issue Size and Price

The total issue size of Aasaan Loans IPO is up to ₹132.00 Cr whereas the issue size of the Emcure Pharma IPO is . The final issue price of Aasaan Loans IPO is ₹120.00 per share and of Emcure Pharma IPO is .

  Aasaan Loans IPO Emcure Pharma IPO
Face Value ₹10 per share ₹10 per share
Issue Price (Lower) ₹114.00 per share
Issue Price (Upper) ₹120.00 per share
Issue Price (Final) ₹120.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 125 shares
Fresh Issue Size 1,10,00,000 shares
Fresh Issue Size (Amount) up to ₹132.00 Cr up to ₹800.00 Cr
OFS Issue Size 1,36,78,839 shares
OFS Issue Size (Amount)
Issue Size Total 1,10,00,000 shares
Issue Size Total (Amount) up to ₹132.00 Cr

IPO Timetable

Aasaan Loans IPO opens on Jun 19, 2024, while Emcure Pharma IPO opens on . The closing date of Aasaan Loans IPO and Emcure Pharma IPO is Jun 21, 2024, and , respectively.

  Aasaan Loans IPO Emcure Pharma IPO
Anchor Bid Date Jun 18, 2024
Issue Open Jun 19, 2024
Issue Close Jun 21, 2024
Basis Of Allotment (Tentative) Jun 24, 2024
Initiation of Refunds (Tentative) Jun 25, 2024
Credit of Share (Tentative) Jun 25, 2024
Listing date (Tentative) Jun 26, 2024
Anchor Lockin End date 1 Jul 24, 2024
Anchor Lockin End date 2 Sep 22, 2024

Financials

Aasaan Loans IPO P/E ratio is , as compared to Emcure Pharma IPO P/E ratio of .

  Aasaan Loans IPO Emcure Pharma IPO
Financial

Akme Fintrade India Ltd Financial Information (Restated)

Akme Fintrade India Ltd's revenue increased by 3.06% and profit after tax (PAT) rose by 283.5% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended31 Dec 202331 Mar 202331 Mar 202231 Mar 2021
Assets417.96390.50374.01455.40
Revenue53.4569.5767.5086.79
Profit After Tax12.2515.804.1216.31
Net Worth217.01204.78136.84130.26
Reserves and Surplus185.34173.11115.03108.45
Total Borrowing195.19177.76230.06317.82
Amount in ₹ Crore
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (₹ in Millions)
  31-March-21 31-March-20 31-March-19
Total Assets 68,073.98 60,040.55 58,104.39
Total Revenue 60,918.06 51,308.60 48,155.90
Profit After Tax 4,185.94 1,006.10 2,029.68
Promoter Shareholding (Pre-Issue) 56.01%
Promoter Shareholding (Post-Issue)
P/E Ratio
Market Cap
ROE 5.64%%
ROCE
Debt/Equity 2.49
EPS ₹3.87
RoNW 5.81%%

Shares Offered

In the Aasaan Loans IPO retail investors (RII) are offered 36,57,500 shares while in Emcure Pharma IPO retail investors are offered 36,57,500 shares. Qualified institutional buyers (QIB) are offered 20,90,000 shares in Aasaan Loans IPO and in Emcure Pharma IPO.

  Aasaan Loans IPO Emcure Pharma IPO
Anchor Investor Reserveration 31,35,000 shares
Market Maker Reserveration
QIB 20,90,000 shares
NII 15,67,500 shares
RII 36,57,500 shares
Employee 5,50,000 shares
Others
Total 78,65,000 shares

Bids Received (Subscription)

Aasaan Loans IPO subscribed 54.49x in total, whereas Emcure Pharma IPO subscribed .

  Aasaan Loans IPO Emcure Pharma IPO
QIB (times) 28.12x
NII (times) 129.98x
Big NII (times) 121.56x
Small NII (times) 146.83x
RII (times) 44.58x
Employee (times) 5.42x
Other (times)
Total (times) 54.49x

Comments

Add a public comment...